CRISPR Therapeutics AG — Director's Dealing 2018

Dec 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-12-21

Reporting Person: Vertex Pharmaceuticals (Europe) Ltd (10% Owner)
Reporting Person: VERTEX PHARMACEUTICALS INC / MA (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-21	Common Shares	P	22742	$22.5784	Acquired	5272742	Direct
2018-12-24	Common Shares	P	2603	$22.9147	Acquired	5275345	Direct
2018-12-24	Common Shares	P	11742	$23.1766	Acquired	5287087	Direct
2018-12-24	Common Shares	P	53655	$24.9687	Acquired	5340742	Direct

Footnotes

F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.

F2: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.46 and $22.70.

F3: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 and $23.00.

F4: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.02 and $23.25.

F5: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.82 and $25.00.